Rozlytrek
NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer
June 15, 2020Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer
Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours
June 18, 2019Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma
Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
